Lakshman Segar, Ph.D.
- Office: HM, Rm 117 Athens, GA 30602USA
- Voice: 706-721-6941
- Fax: 706-721-6491
- Email: email@example.com
Associate Professor , University of Georgia 2011-Present
Research Pharmacologist , VA Medical Center 2011-Present
Assistant Professor , Penn State University 2000-2011
Core Lab Professor , GCRC, Penn State University 2008-2010
Research Associate , Penn State University 1998-2000
Postdoctoral Fellow , University of British Columbia 1996-1998
Postdoctoral Fellow , University of Saskatchewan 1994-1996
Graduate Teaching Assistant , University of Saskatchewan 1992-1993
Ph.D., Pharmacology , University of Saskatchewan 1990-1994
Diabetic vascular complications: Atherosclerosis, restenosis after angioplasty, vascular injury, dyslipidemia, smooth muscle cell phenotype, cell proliferation, cell differentiation, signal transduction mechanisms, platelet-derived growth factor receptor signaling, insulin receptor signaling, and glucose transporters.
Diabetic retinopathy: Neurovascular complications, retinal ganglion cells, retinal endothelial cells, cell survival, apoptosis, signal transduction mechanisms, platelet-derived growth factor receptor signaling, and insulin receptor signaling.
Grant-In-Aid award from NIH/NHLBI (R01 Grant, 08/2010-04/2014)
Grant-In-Aid awards from National Diabetes Research funding agencies (NIH/NIDDK-R21
Grant, 09/2005-06/2008; JDRF-Regular Research Grant, 08/2005-07/2009; and ADA-Innovation Award) Beginning Grant-In-Aid awards from American Heart Association, Pennsylvania-Delaware Affiliate (07/1999-06/2002; 07/2002-12/2004)
PSU Bridge Grant/PA Dept. of Health/Tobacco Settlement Fund (07/2009-06/2011)
Pennsylvania Lions Sight Conservation and Eye Research Foundation award (09/2003-09/2004; 12/2009-04/2011)
Postdoctoral Fellowship award, Health Services Utilization and Research Commission, Saskatoon, Saskatchewan, Canada
Graduate Scholarship, College of Graduate Studies and Research, University of Saskatchewan, Saskatoon, Saskatchewan, Canada (1990-1994)
Appointed to the Editorial Board of the Journal of Pharmacology and Clinical Toxicology
Session Lecture at the 7th International Conference on Drug Discovery & Therapy, held at the University of Sharjah, UAE, February 15-18, 2016. The title of his presentation was “Diabetic Ketoacidosis: An Adverse Event Associated with SGLT2 Inhibitor Therapy”.
Osman I. and Segar L. Pioglitazone, a PPAR agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling. Biochem Pharmacol. 2015 (Nov 28): 1-17
Pyla, R., Poulose, N., Jun, J.Y., and Segar, L. Expression of conventional and novel glucose transporters, GLUT1, -9, -10, -12, in vascular smooth muscle cells. Am J Physiol:Cell Physiol. 304: C574-C589; 2013.
Jun, J.Y., Ma, Z., and Segar, L. Spontaneously diabetic Ins2+/Akita:ApoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. Am J Physiol:Endocrinol Metab. 301: E145-E154; 2011.
Zhao, Y., Biswas, S.K., McNulty, P.H., Kozak, M., Jun, J.Y., and Segar, L. PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates. Am J Physiol:Cell Physiol. 300: C1375-C1385; 2011.
Biswas, S.K., Zhao, Y. and Sandirasegarane, L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vis. 15: 1599-1610; 2009.
Houck, K.L., Fox, T.E., Sandirasegarane, L. and Kester M. Ether-linked diglycerides inhibit vascular smooth muscle cell growth via decreased MAPK and PI3K/Akt signaling. Am J Physiol:Heart Circ Physiol. 295: H1657-H1668; 2008.
Biswas, S.K., Zhao, Y., Nagalingam, A., Gardner, T.W. and Sandirasegarane, L. PDGF- and Insulin/IGF-1-specific distinct modes of Class IA PI 3-kinase activation in normal rat retinas & RGC-5 retinal ganglion Cells. Invest Ophthal Vis Sci. 49: 3687-3698; 2008.
Antonetti, D.A., Barber, A.J., Bronson, S.K., Freeman, W.M., Gardner, T.W., Jefferson, L.S., Kester, M., Kimball, S.R., Krady, J.K., LaNoue, K.F., Norbury, C.C., Quinn, P.G., Sandirasegarane, L. and Simpson, I.A.. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes 55: 2401-2411; 2006.
Reiter, C.E.N., Wu, X., Sandirasegarane, L., Nakamura, M., Gilbert, K.A., Singh, R.S.J., Fort, P.E., Antonetti, D.A. and Gardner, T.W. Diabetes reduces basal retinal insulin receptor signaling: Reversal with systemic and local insulin. Diabetes 55: 1148-1156; 2006.
Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L. and Robertson, G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64: 7002-7010; 2004.
Sandirasegarane, L. and Diamond J. Pertussis toxin-sensitive G protein but not NO/cGMP pathway mediates the negative inotropic effect of carbachol in adult rat cardiomyocytes. Pharmacology 70: 46-56; 2004.
Reiter, C.E.N., Sandirasegarane, L., Wolpert, E.B., Klinger, M., Simpson, I.A., Barber, A.J., Antonetti, D.A., Kester, M. and Gardner, T.W. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol:Endocrinol Metab. 285: E763-E774; 2003.
Bourbon, N., Sandirasegarane, L. and Kester, M. Ceramide-induced inhibition of Akt is mediated through PKCzeta: implications for growth arrest. J Biol Chem. 277: 3286-3292; 2002.
Sandirasegarane, L. and Kester, M. Enhanced stimulation of Akt-3/protein kinase B- in human aortic smooth muscle cells. Biochem Biophys Res Commun. 283: 158-163; 2001.
Charles, R., Sandirasegarane, L., Yun, J., Bourbon, N., Wilson, R., Rothstein, R.P., Levison, S. and Kester, M. Ceramide-coated balloon catheters limit neointimal hyperplasia following stretch injury in carotid arteries. Circ Res. 87: 282-288; 2000.
Sandirasegarane, L., Charles, R., Bourbon, N. and Kester, M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol:Cell Physiol. 279: C225-C235; 2000.
Sandirasegarane, L. and Diamond, J. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation. J Mol Cell Cardiol. 31: 799-808; 1999.